A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Cytomegalovirus-specific T-cell therapy Atara/MSKCC (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Atara Biotherapeutics
- 27 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 27 Feb 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 05 Apr 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.